MarketPulse

Phase 1 clinical trial

15 articles
BenzingaBenzinga··Globe Newswire

Pathos AI Acquires DeuterOncology to Commercialize Next-Gen MET Inhibitor

Pathos AI acquires majority stake in DeuterOncology to advance DO-2, a MET inhibitor showing 100% tumor shrinkage in Phase 1 with superior safety profile.
AZNTEMPhase 1 clinical trialoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Molecular Partners Ag

Molecular Partners' MP0317 Shows Promise in Nature Cancer, Sparks CD40 Agonist Competition

Molecular Partners published positive Phase 1 data for MP0317, a CD40 agonist, in Nature Cancer, demonstrating tumor microenvironment remodeling with favorable safety in advanced cancer patients.
MOLNPhase 1 clinical trialimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Bioage Labs, Inc.

BioAge's BGE-102 Shows Best-in-Class Inflammation Reduction in Phase 1 Trial

BioAge's BGE-102 achieves best-in-class hsCRP reductions of ≥85% in Phase 1, with excellent tolerability. Phase 2 cardiovascular and diabetic macular edema trials planned for mid-2026.
BIOAPhase 1 clinical trialdiabetic macular edema
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Revolution Medicines Advances KRAS G12D Lung Cancer Drug With 52% Response Rate

Revolution Medicines reports promising Phase 1 data for zoldonrasib, showing 52% response rate in previously treated KRAS G12D lung cancer patients with manageable safety profile.
RVMDRVMDWPhase 1 clinical trialoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Boundless Bio

Boundless Bio Touts First-in-Class Breast Cancer Drug as AACR Data Bolsters Rare DNA Target

Boundless Bio presented preclinical data for BBI-940, an oral kinesin degrader targeting extrachromosomal DNA in breast cancer, with Phase 1 trials underway.
BOLDbreast cancerPhase 1 clinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Radiopharm Theranostics Advances RAD202 Trial to Higher Dose Cohort

Radiopharm Theranostics advances RAD202 radiopharmaceutical trial to higher dose cohort following positive safety review, remaining on track for 2026 Phase 1 completion.
RADXPhase 1 clinical trialoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Adaptin Bio Gains OTCQB Listing as Glioblastoma Drug Enters Clinical Trials

Adaptin Bio ($APTN) approved for OTCQB quotation. Lead program APTN-101, a brain bispecific T cell engager for glioblastoma, receives FDA clearance for Phase 1 trials.
APTNPhase 1 clinical trialglioblastoma
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Zymeworks Wins FDA Fast Track for Cancer Drug ZW191, Accelerating Path to Market

Zymeworks secures FDA Fast Track designation for ZW191, an ovarian cancer antibody-drug conjugate, accelerating development timelines.
ZYMEantibody-drug conjugatePhase 1 clinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Radiopharm Theranostics

Radiopharm Theranostics Advances Novel Prostate Cancer Therapy With First Patient Dosed

Radiopharm Theranostics doses first patient in Phase 1 trial of RAD 402, a targeted radioimmune therapy for advanced prostate cancer, with data expected H2 2026.
RADXmonoclonal antibodyPhase 1 clinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Proqr Therapeutics N.V.

ProQR Advances Gene Therapy Pipeline as Cash Runway Extends to Mid-2027

ProQR reported €92.4M cash, advanced lead program AX-0810 into Phase 1, and achieved $4.5M in Eli Lilly milestones, projecting runway into mid-2027.
LLYPRQRPhase 1 clinical trialbiotech pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Arvinas to Showcase ARV-102 Parkinson's Data at Major Neurology Conference

Arvinas will present Phase 1 data for ARV-102, a PROTAC LRRK2 degrader, at AD/PD 2026 conference in Copenhagen, with Phase 1b trial planned for progressive supranuclear palsy.
ARVNPhase 1 clinical trialParkinson's disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Keros Therapeutics' Rinvatercept Shows Promise in Neuromuscular Disease Trial

Keros Therapeutics presented Phase 1 data for rinvatercept showing good tolerability and increased muscle mass, planning Phase 2 trials in DMD and ALS.
KROSPhase 1 clinical trialPhase 2 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Septerna's SEP-631 Shows Promise in Mast Cell Disease Treatment

Septerna reports positive Phase 1 data for SEP-631, an experimental oral treatment for mast cell-driven diseases, with plans for Phase 2b development beginning late 2026.
SEPNchronic spontaneous urticariaoral small-molecule
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Juvenescence Advances PAI-1 Program With Phase 1 Success, Expands Leadership Team

Juvenescence completes Phase 1 trial of PAI-1 inhibitor MDI-2517 with positive safety results. Company expands leadership and plans Phase 2 study in late 2026.
PFEbiotechclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Atea's AT-587 Shows Promise as Potential First HEV Treatment in Preclinical Study

Atea's AT-587 shows promise as first potential HEV treatment, demonstrating 30-150x greater antiviral activity than existing agents in preclinical studies. Phase 1 trials expected mid-2026.
AVIRPhase 1 clinical trialHepatitis E Virus